Recently, many studies have drawn attention to the possibility of imaging estrogen-receptor-positive breast cancer with a high-affinity ligand such as 17β-(16α-[125I]iodo)-estradiol (I-E2). We tried to determine the most suitable time and dose for imaging with this compound, using uteri of mature Sprague-Dawley rats. Although the uptake of I-E2 in the target organ (uterus) reached its peak 1 h after subcutaneous injection, the ratio of uptake in the target organ to that in nontarget organs (lung and muscle) peaked at 4 h. We also found that this ratio decreased as the dose increased. The clearest image was available 4 h after the dose meeting the minimum requirement for imaging was administered. An imaging trial of dimethylbenzanthracene (DMBA)-induced mammary carcinoma is also demonstrated.
This is a preview of subscription content, log in to check access.
Buy single article
Instant access to the full article PDF.
Price includes VAT for USA
Subscribe to journal
Immediate online access to all issues from 2019. Subscription will auto renew annually.
This is the net price. Taxes to be calculated in checkout.
Arunachalam T, Longcope C, Capsi E (1979) Iodoestrogens, syntheses, and interaction with uterine receptors. J Biol Chem 254:5900–5905
Eckelman WC, Reba RC, Gibson RE, Rzeszotarski WJ, Vieras F, Mazaitis JK, Francis B (1981) Receptorbinding radiotracers: A class of potential radiopharmaceuticals. J Nucl Med 20:350–357
Gatley SJ, Shaughnessy WJ, Inhorn L, Lieberman LM (1981) Studies with 17β(16α-[125I]iodo)estradiol, an estrogen receptorbinding radiopharmaceutical, in rats bearing mammary tumors. J Nucl Med 22:459–464
Hochberg RB (1979) Iodo-125-labeled estradiol: A gammaemitting analog of estradiol that binds to the estrogen receptor. Science 205:1138–1140
Hochberg RB, Rosner W (1980) Interaction of 16α-[125I]iodoestradiol with estrogen receptor and other binding proteins. Proc Natl Acad Sci USA 77:328–332
Katzenellenbogen JA, Hsiung HM, Carlson KE, McGuire WL, Kraay RJ, Katzenellenbogen BS (1975) Characterization of the binding and estrogenic activity of iodinated hexestrol derivatives, in vitro and in vivo. Biochemistry 14:1742–1749
Katzenellenbogen JA, Senderoff SG, McElvany KD, O'Brien HA, Welch MJ (1981) 16α-[77Br]bromoestradiol-17: A high specific activity, gamma-emitting tracer with uptake in rat uterus and induced mammary tumors. J Nucl Med 22:42–47
Knight WA, Livingston RB, Gregory EJ, McGuire WL (1979) Estrogen receptor as an independent prognostic factor for early recurrence in breast cancer. Cancer Res 37:4669–4671
Longcope C, Arunachalam T, Rafkind I, Capsi E (1981) Biological activity of 125I and 127I estradiol analogs in vitro and in vivo. J Steroid Biochem 14:261–269
McElvany KD, Carlson KE, Welch MJ, Senderoff SG, Katzenellenbogen JA, the Los Alamos Medical Radioisotope Group (1982) In vivo comparison of 16α-[77Br]bromo-estradiol-17β and 16α-[125I]iodo-estradiol-17β. J Nucl Med 23:420–424
McGuire WL, Carbone PP, Vollmer PP (1975) Estrogen receptors in human breast cancer. Raven Press, New York
Mazaitis JK, Gibson RE, Komai T, Eckelman WC, Francis B, Reba RC (1980) Radioiodinated estrogen derivatives. J Nucl Med 21:142–146
Ratajczak T, Sheppard PN, Capon RJ, Hähnel R (1981) The synthesis and study of some potential affinity labeling reagents. Steroids 38:537–555
About this article
Cite this article
Noguchi, S., Koyama, H. & Nakano, S. Dose-dependent change in tissue uptake of 17β-(16α-[125I]iodo)-estradiol in female rats: Application to external imaging of mammary carcinoma. Eur J Nucl Med 9, 490–493 (1984). https://doi.org/10.1007/BF00263251
- Breast Cancer
- Target Organ
- Minimum Requirement
- Mammary Carcinoma